133 related articles for article (PubMed ID: 22038727)
1. Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Sep; 29(3):2284-90. PubMed ID: 22038727
[TBL] [Abstract][Full Text] [Related]
2. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
[TBL] [Abstract][Full Text] [Related]
3. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
4. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
5. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
[TBL] [Abstract][Full Text] [Related]
6. No compensation in VEGF expression follows antisense suppression of BCL-2 activity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2012; 26(6):937-40. PubMed ID: 23160675
[TBL] [Abstract][Full Text] [Related]
7. Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2014; 28(5):867-70. PubMed ID: 25189901
[TBL] [Abstract][Full Text] [Related]
8. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
9. Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2013; 30(3):599. PubMed ID: 23677569
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
Rubenstein M; Guinan P
In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
[TBL] [Abstract][Full Text] [Related]
11. Bax expression remains unchanged following antisense treatment directed against BCL-2.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2011 Sep; 28(3):852-8. PubMed ID: 20422317
[TBL] [Abstract][Full Text] [Related]
12. In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2011 Dec; 3(6):243-50. PubMed ID: 22164193
[TBL] [Abstract][Full Text] [Related]
13. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
14. In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2011 Apr; 3(2):51-7. PubMed ID: 21869905
[TBL] [Abstract][Full Text] [Related]
15. Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2015; 29(6):687-93. PubMed ID: 26546525
[TBL] [Abstract][Full Text] [Related]
16. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2013 Apr; 5(2):85-93. PubMed ID: 23554843
[TBL] [Abstract][Full Text] [Related]
19. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
[TBL] [Abstract][Full Text] [Related]
20. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
